| Members |
acceptabilityId |
| 5,8,11,14-eicosatetraenoic acid |
Acceptable (foundation metadata concept) |
| 5,8,11-eicosatrienoic acid |
Preferred (foundation metadata concept) |
| 5,8,11-eicosatrienoic acid (substance) |
Preferred (foundation metadata concept) |
| 5-(3,4-diacetoxybut-1-ynyl)-2,2'-bithiophene deacetylase |
Preferred (foundation metadata concept) |
| 5-(3,4-diacetoxybut-1-ynyl)-2,2'-bithiophene deacetylase (substance) |
Preferred (foundation metadata concept) |
| 5-ASA |
Acceptable (foundation metadata concept) |
| 5-Aminolevulinate synthase |
Preferred (foundation metadata concept) |
| 5-Aminolevulinate synthase (substance) |
Preferred (foundation metadata concept) |
| 5-Chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one Kathon (3:1 in water) |
Preferred (foundation metadata concept) |
| 5-Chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one Kathon (3:1 in water) (product) |
Preferred (foundation metadata concept) |
| 5-Chloro-7-iodo-quinolinol |
Preferred (foundation metadata concept) |
| 5-Chloro-7-iodo-quinolinol |
Preferred (foundation metadata concept) |
| 5-Chloro-7-iodo-quinolinol (product) |
Preferred (foundation metadata concept) |
| 5-Chloro-7-iodo-quinolinol (substance) |
Preferred (foundation metadata concept) |
| 5-FC |
Acceptable (foundation metadata concept) |
| 5-Fluorocytosine measurement |
Acceptable (foundation metadata concept) |
| 5-HIAA - 5-Hydroxyindole acetic acid |
Acceptable (foundation metadata concept) |
| 5-HIAA - 5-Hydroxyindole acetic acid |
Acceptable (foundation metadata concept) |
| 5-HIAA - 5-Hydroxyindole acetic acid |
Acceptable (foundation metadata concept) |
| 5-HIAA quantitative, urine |
Acceptable (foundation metadata concept) |
| 5-HPETE |
Acceptable (foundation metadata concept) |
| 5-HT - 5-hydroxytryptamine |
Acceptable (foundation metadata concept) |
| 5-HT secreting neuroendocrine tumor |
Preferred (foundation metadata concept) |
| 5-HT3 receptor antagonist |
Preferred (foundation metadata concept) |
| 5-HT3 receptor antagonist |
Preferred (foundation metadata concept) |
| 5-HT3 receptor antagonist-containing product |
Preferred (foundation metadata concept) |
| 5-HT3-receptor antagonist adverse reaction |
Preferred (foundation metadata concept) |
| 5-HT3-receptor antagonist allergy |
Acceptable (foundation metadata concept) |
| 5-HT3-receptor antagonist overdose |
Preferred (foundation metadata concept) |
| 5-HT3-receptor antagonist overdose of undetermined intent |
Preferred (foundation metadata concept) |
| 5-HT3-receptor antagonist poisoning |
Preferred (foundation metadata concept) |
| 5-HT3-receptor antagonist poisoning of undetermined intent |
Preferred (foundation metadata concept) |
| 5-He |
Acceptable (foundation metadata concept) |
| 5-Hydroxy-indoleacetic acid |
Preferred (foundation metadata concept) |
| 5-Hydroxy-indoleacetic acid (substance) |
Preferred (foundation metadata concept) |
| 5-Hydroxyhexanoate measurement |
Preferred (foundation metadata concept) |
| 5-Hydroxyhexanoate measurement (procedure) |
Preferred (foundation metadata concept) |
| 5-Hydroxyindoleacetic acid |
Preferred (foundation metadata concept) |
| 5-Hydroxyindoleacetic acid (substance) |
Preferred (foundation metadata concept) |
| 5-Hydroxyindoleacetic acid measurement |
Preferred (foundation metadata concept) |
| 5-Hydroxyindoleacetic acid measurement (procedure) |
Preferred (foundation metadata concept) |
| 5-Hydroxyindoleacetic acid measurement, quantitative, urine |
Preferred (foundation metadata concept) |
| 5-Hydroxyindoleacetic acid measurement, quantitative, urine (procedure) |
Preferred (foundation metadata concept) |
| 5-Hydroxyindoleacetic acid/creatinine ratio measurement |
Preferred (foundation metadata concept) |
| 5-Hydroxyindoleacetic acid/creatinine ratio measurement (procedure) |
Preferred (foundation metadata concept) |
| 5-Hydroxytryptamine measurement |
Acceptable (foundation metadata concept) |
| 5-Hydroxytryptamine release |
Acceptable (foundation metadata concept) |
| 5-Hydroxytryptamine release measurement |
Preferred (foundation metadata concept) |
| 5-Hydroxytryptamine release measurement (procedure) |
Preferred (foundation metadata concept) |
| 5-Hydroxytryptamine uptake |
Acceptable (foundation metadata concept) |
| 5-Hydroxytryptamine uptake measurement |
Preferred (foundation metadata concept) |
| 5-Hydroxytryptamine uptake measurement (procedure) |
Preferred (foundation metadata concept) |
| 5-Hydroxytryptamine-3-receptor antagonist adverse reaction |
Acceptable (foundation metadata concept) |
| 5-Hydroxytryptamine-3-receptor antagonist adverse reaction (disorder) |
Preferred (foundation metadata concept) |
| 5-Hydroxytryptamine-3-receptor antagonist overdose |
Acceptable (foundation metadata concept) |
| 5-Hydroxytryptamine-3-receptor antagonist overdose (disorder) |
Preferred (foundation metadata concept) |
| 5-Hydroxytryptamine-3-receptor antagonist overdose of undetermined intent |
Acceptable (foundation metadata concept) |
| 5-Hydroxytryptamine-3-receptor antagonist overdose of undetermined intent (disorder) |
Preferred (foundation metadata concept) |
| 5-Hydroxytryptamine-3-receptor antagonist poisoning |
Acceptable (foundation metadata concept) |
| 5-Hydroxytryptamine-3-receptor antagonist poisoning (disorder) |
Preferred (foundation metadata concept) |
| 5-Hydroxytryptamine-3-receptor antagonist poisoning of undetermined intent |
Acceptable (foundation metadata concept) |
| 5-Hydroxytryptamine-3-receptor antagonist poisoning of undetermined intent (disorder) |
Preferred (foundation metadata concept) |
| 5-Hydroxytryptophan measurement |
Preferred (foundation metadata concept) |
| 5-Hydroxytryptophan measurement (procedure) |
Preferred (foundation metadata concept) |
| 5-O-(4-coumaroyl)-D-quinate 3'-monooxygenase |
Preferred (foundation metadata concept) |
| 5-O-(4-coumaroyl)-D-quinate 3'-monooxygenase (substance) |
Preferred (foundation metadata concept) |
| 5-O-(4-coumaroyl)-D-quinate/shikimate 3'-hydroxylase |
Acceptable (foundation metadata concept) |
| 5-OH indole acetic acid (& level (& urine)) |
Preferred (foundation metadata concept) |
| 5-OH indole acetic acid (& level (& urine)) |
Preferred (foundation metadata concept) |
| 5-OH indole acetic acid (& level (& urine)) (procedure) |
Preferred (foundation metadata concept) |
| 5-OH indole acetic acid (& level (& urine)) (procedure) |
Preferred (foundation metadata concept) |
| 5-Oxoprolinase deficiency |
Preferred (foundation metadata concept) |
| 5-Oxoprolinase deficiency (disorder) |
Preferred (foundation metadata concept) |
| 5-Oxoproline |
Preferred (foundation metadata concept) |
| 5-Oxoproline (substance) |
Preferred (foundation metadata concept) |
| 5-Oxoproline + pipecolate |
Preferred (foundation metadata concept) |
| 5-Oxoproline + pipecolate (substance) |
Preferred (foundation metadata concept) |
| 5-Oxoproline measurement |
Preferred (foundation metadata concept) |
| 5-Oxoproline measurement (procedure) |
Preferred (foundation metadata concept) |
| 5-Oxoprolinuria |
Acceptable (foundation metadata concept) |
| 5-WAY LEPTOSPIROSIS VACCINE |
Preferred (foundation metadata concept) |
| 5-WAY LEPTOSPIROSIS VACCINE (product) |
Preferred (foundation metadata concept) |
| 5-alpha reductase deficiency |
Acceptable (foundation metadata concept) |
| 5-alpha reductase inhibitor |
Preferred (foundation metadata concept) |
| 5-alpha reductase inhibitor |
Preferred (foundation metadata concept) |
| 5-alpha reductase inhibitor (disposition) |
Preferred (foundation metadata concept) |
| 5-alpha reductase inhibitor-containing product |
Preferred (foundation metadata concept) |
| 5-alpha tetrahydro-11-dehydrocorticosterone |
Preferred (foundation metadata concept) |
| 5-alpha tetrahydro-11-dehydrocorticosterone (substance) |
Preferred (foundation metadata concept) |
| 5-alpha-Tetrahydrocortisol measurement |
Preferred (foundation metadata concept) |
| 5-alpha-Tetrahydrocortisol measurement (procedure) |
Preferred (foundation metadata concept) |
| 5-alpha-dihydrotestosterone |
Acceptable (foundation metadata concept) |
| 5-alpha-tetrahydrocortisol |
Preferred (foundation metadata concept) |
| 5-alpha-tetrahydrocortisol (substance) |
Preferred (foundation metadata concept) |
| 5-amino-4-imidazole carboxamide ribosiduria |
Preferred (foundation metadata concept) |
| 5-amino-4-imidazole carboxamide ribosiduria (disorder) |
Preferred (foundation metadata concept) |
| 5-amino-6-(5-phosphoribosylamino) uracil reductase |
Preferred (foundation metadata concept) |
| 5-amino-6-(5-phosphoribosylamino) uracil reductase (substance) |
Preferred (foundation metadata concept) |
| 5-aminolevulinate |
Preferred (foundation metadata concept) |
| 5-aminolevulinate (substance) |
Preferred (foundation metadata concept) |
| 5-aminolevulinate dehydratase |
Acceptable (foundation metadata concept) |
FHIR